{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:03:34Z","timestamp":1789589014464,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03395-0","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:14:26Z","timestamp":1789586066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thrombotic and ischemic event reporting with anticoagulant reversal agents: a multi-agent FAERS pharmacovigilance study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-9715","authenticated-orcid":false,"given":"Hasan Burak","family":"Isleyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevil Tugrul","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusret","family":"Acikgoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Uluganyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguzhan","family":"Abanoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Danisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertugrul","family":"Okuyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"3395_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","volume":"76","author":"GF Tomaselli","year":"2020","unstructured":"Tomaselli GF, Mahaffey KW, Cuker A et al (2020) 2020 ACC Expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol 76:594\u2013622. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.053","journal-title":"J Am Coll Cardiol"},{"key":"3395_CR2","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","volume":"390","author":"SJ Connolly","year":"2024","unstructured":"Connolly SJ, Sharma M, Cohen AT et al (2024) Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med 390:1745\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa2313040","journal-title":"N Engl J Med"},{"key":"3395_CR3","unstructured":"U.S. Food and Drug Administration. Update on the Safety of Andexxa by AstraZeneca: FDA Safety Communication. December 18, 2025. Accessed August 3, (2026)"},{"key":"3395_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack Jr","year":"2017","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J et al (2017) Idarucizumab for dabigatran reversal: full cohort analysis. N Engl J Med 377:431\u2013441. https:\/\/doi.org\/10.1056\/NEJMoa1707278","journal-title":"N Engl J Med"},{"key":"3395_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Development and Statement. Drug Saf 47:575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"key":"3395_CR6","unstructured":"E2D(R1) (March 2026) Food and Drug Administration. Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports. Final Guidance"},{"key":"3395_CR7","unstructured":"Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization (2025) Introductory Guide MedDRA Version 28.0. March"},{"key":"3395_CR8","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Monitoring System (AEMS) Latest Quarterly Data Files [formerly FDA Adverse Event Reporting System (FAERS)]. Accessed August 3, (2026)"},{"key":"3395_CR9","unstructured":"European Medicines Agency and Heads of Medicines Agencies (2017) Guideline on Good Pharmacovigilance Practices: Module IX Addendum I - Methodological Aspects of Signal Detection from Spontaneous Reports of Suspected Adverse Reactions. EMA\/209012\/2015"},{"key":"3395_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3395_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3395_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3395_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on control of anticoagulation of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3395_CR14","doi-asserted-by":"publisher","first-page":"100100","DOI":"10.1016\/j.bvth.2025.100100","volume":"2","author":"IMS Hoornstra","year":"2025","unstructured":"Hoornstra IMS, Zhao J, Middelveld H et al (2025) Procoagulant off-target effect of the direct oral anticoagulant reversal agent Andexanet alfa. Blood Vessel Thromb Hemost 2(4):100100. https:\/\/doi.org\/10.1016\/j.bvth.2025.100100","journal-title":"Blood Vessel Thromb Hemost"},{"key":"3395_CR15","doi-asserted-by":"publisher","first-page":"17838","DOI":"10.1073\/pnas.1310444110","volume":"110","author":"JP Wood","year":"2013","unstructured":"Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE (2013) Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A 110:17838\u201317843. https:\/\/doi.org\/10.1073\/pnas.1310444110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3395_CR16","doi-asserted-by":"publisher","first-page":"103201","DOI":"10.1016\/j.rpth.2025.103201","volume":"9","author":"AJ Xiang","year":"2025","unstructured":"Xiang AJ, Lopes Sadafi S, Principato R et al (2025) Andexanet alfa vs standard of care for factor Xa inhibitor-induced intracranial hemorrhage: a systematic review and meta-analysis. Res Pract Thromb Haemost 9(7):103201. https:\/\/doi.org\/10.1016\/j.rpth.2025.103201","journal-title":"Res Pract Thromb Haemost"},{"key":"3395_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajem.2025.07.037","volume":"97","author":"MA Rech","year":"2025","unstructured":"Rech MA, Budde E, Evans CT et al (2025) Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans. Am J Emerg Med 97:97\u2013102. https:\/\/doi.org\/10.1016\/j.ajem.2025.07.037","journal-title":"Am J Emerg Med"},{"key":"3395_CR18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJ Jr, Eikelboom JW et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375:1131\u20131141. https:\/\/doi.org\/10.1056\/NEJMoa1607887","journal-title":"N Engl J Med"},{"key":"3395_CR19","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","volume":"91","author":"R Harpaz","year":"2012","unstructured":"Harpaz R, DuMouchel W, Shah NH et al (2012) Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther 91:1010\u20131021. https:\/\/doi.org\/10.1038\/clpt.2012.50","journal-title":"Clin Pharmacol Ther"},{"key":"3395_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM (2014) The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf 37:283\u2013294. https:\/\/doi.org\/10.1007\/s40264-014-0150-2","journal-title":"Drug Saf"},{"key":"3395_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"3395_CR22","doi-asserted-by":"publisher","unstructured":"Chen T, Luo D, Xu X, Su A (2026) Persistent andexanet thromboembolic signals among reversal agents in FAERS. Lett Drug Des Discov 100484. https:\/\/doi.org\/10.1016\/j.lddd.2026.100484","DOI":"10.1016\/j.lddd.2026.100484"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03395-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03395-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03395-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:14:29Z","timestamp":1789586069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03395-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":22,"alternative-id":["3395"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03395-0","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"13 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used publicly available de-identified FAERS\/AEMS quarterly data. Institutional review board approval and informed consent were not required.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}